Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Nephropathic juvenile cystinosis is the intermediate form, in regards to severity and age of onset, of cystinosis, a metabolic disease characterized by an accumulation of cystine inside the lysosomes that causes damage in different organs and tissues, particularly in the kidneys and eyes.
Features include always present findings: Photophobia, Protein in the urine (proteinuria), Corneal crystals, and Elevated intracellular cystine. 9 total HPO annotations.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Eyes | 3 | Retinal pigment epithelial mottling, Damage to the retina (retinopathy), Corneal crystals |
Kidneys and urinary system | 2 | Stage 5 chronic kidney disease, Protein in the urine (proteinuria) |
Growth and development | 1 | Growth abnormality |
Bones and joints | 1 | Rickets |
Age of onset: adolescence.
Although phenotypes may overlap, three clinical phenotypes of cystinosis are recognized: nephropathic (the most severe form that presents in infancy), later-onset (juvenile), and non-nephropathic (ocular) cystinosis .
The clinical characteristics of untreated nephropathic cystinosis include poor weight gain, growth deficiency, renal tubular Fanconi syndrome, renal glomerular failure, and non-renal involvement of a variety of tissues and organ systems. Treatment with cysteamine allows depletion of lysosomal cystine in most tissues. Although cysteamine does not cure the disease, it dramatically improves the overall prognosis and life span . Growth. Infants with untreated nephropathic cystinosis typically have normal birth measurements.
Source: GeneReviews — "Cystinosis"
CTNS encodes cystinosin, lysosomal cystine transporter (367 aa). Cystine/H(+) symporter that mediates export of cystine, the oxidized dimer of cysteine, from lysosomes. Highest expression in Testis (48.4 TPM) and Nerve Tibial (37.2 TPM).
Juvenile nephropathic cystinosis is associated with mutations in the CTNS gene on chromosome 17.
The CTNS protein participates in CTNS cotransports CySS-, H+ from lysosomal lumen to cytosol pathway.
CTNS is classified as a druggable target (Transporter category) with score 2.4.
Some genotype-phenotype correlations have been reported :
Truncating CTNS pathogenic variants and the 57-kb deletion result in nephropathic cystinosis when present in homozygous form .
Individuals with apparent residual activity (and lower levels of cystine accumulation in leukocytes) often have missense pathogenic variants in CTNS . Individuals with later-onset (juvenile) cystinosis or non-nephropathic (ocular) cystinosis generally have one severe CTNS pathogenic variant, typical for nephropathic cystinosis, and one mild pathogenic variant. The mild pathogenic variants include c.589GA (p.Gly197Arg) and c.853-3CG .
The pathogenic variant c.416CT (p.Ser139Phe) may cause later-onset (juvenile) phenotype when the other allele is a nonsense variant.
Source: GeneReviews — "Cystinosis"
Nephropathic cystinosis should be suspected in infants and young children with the following clinical, laboratory, and imaging features and family history.
Clinical features
Typically, birth weight and initial growth are normal. Poor weight gain and growth deficiency occurs by age six to 12 months.
Vomiting and feeding difficulties
Severe polyuria, polydipsia, and dehydration
Progressive rachitic skeletal changes; failure to walk at a normal age
Tetany
Corneal crystals, typically observed by slit lamp examination in most individuals by age 12 months and in virtually all individuals by age 18 months (See .)
Laboratory features
Source: GeneReviews — "Cystinosis"
Renal tubular Fanconi syndrome. Untreated nephropathic cystinosis is the most common identifiable cause of renal tubular Fanconi syndrome in childhood. Genetic disorders associated with renal tubular Fanconi syndrome are listed in . Table 2. Genetic Disorders Associated with Renal Tubular Fanconi Syndrome in the Differential Diagnosis of Cystinosis
Gene(s) | Disorder | MOI | Features of Disorder | Comment |
|---|---|---|---|---|
Wilson disease | AR | Can manifest in individuals age 3 yrs to 70 yrs as hepatic, neurologic, or psychiatric disturbances, or a combination of these. Other multisystem involvement can include eyes (Kayser-Fleischer rings), hemolytic anemia, kidneys, endocrine glands, heart. |
Genetic testing for CTNS is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for juvenile nephropathic cystinosis has been reported in the published literature.
No approved treatments are currently available for juvenile nephropathic cystinosis. The disease remains an area of unmet medical need.
Expert guidance on the multidisciplinary management of cystinosis in adolescent and adult patients is available, including clinical recommendations [, , , ].
Evaluations Following Initial Diagnosis
Table 3.
Cystinosis: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| • Height weight, plotted on age-appropriate growth charts
Assessment of feeding nutrition
Lipid panel to assess nutritional status in those w/feeding difficulties requiring formula feeding by gastrostomy tube
|
| • Serum concentrations of creatinine, phosphate, bicarbonate, potassium
Urine concentrations of creatinine, phosphate, bicarbonate, sodium, potassium, magnesium, glucose, protein
Quantitative measurement of urine amino acids GFR or creatinine clearance test
| Measurement of urine amino acids helps to identify severity of renal Fanconi syndrome.1
Skeletal radiographs DXA scan to assess skeletal involvement/ rickets | Beginning at age ~2 yrs
Renal US to assess for nephrocalcinosis |
| Dental eval to assess abnormal dental eruption | Beginning at age ≥1 yr
Eyes | Ophthalmologic eval incl:
Slit lamp exam of cornea for cystine crystals
ERG to assess retinal involvement
Fundoscopic exam to assess for intracranial hypertension
|
| Thyroid function studies to assess hypothyroidism |
Measurement of serum concentration of testosterone, FSH, LH | Beginning in pre- postpubertal males
Source: GeneReviews — "Cystinosis"
Avoid the following:
Dehydration, which compromises remaining kidney function
Sun exposure, which can exacerbate photophobia
Source: GeneReviews — "Cystinosis"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Cystinosis"
1 trial found
To monitor existing manifestations, the individual's response to supportive care, and the emergence of new manifestations, the evaluations summarized in are recommended. Clinical and laboratory examinations should be performed in individuals with nephropathic cystinosis according to disease severity and may include renal, endocrine, ophthalmologic, neurologic, and cardiac examinations . Table 6. Cystinosis: Recommended Surveillance
System/Concern | Evaluation | Frequency |
|---|---|---|
Growth/Nutrition | Height weight plotted on age-appropriate growth charts | Every 3-6 mos throughout childhood until growth is complete; Assess for difficulty w/chewing, aspiration, dysphasia, weight loss, mealtimes of long duration, respiratory symptoms incl respiratory infection. |
Kidney function | Nephrology eval incl kidney function tests (urine albumin; serum creatinine [to calculate eGFR]) | Every 3-6 mos based on severity of kidney impairment Metabolic |
(incl bone disease) | Metabolic specialist eval incl serum electrolytes, calcium, phosphate, serum alkaline phosphatase, intact parathyroid hormone | Annually or more frequently as needed Skeletal radiographs DXA scan to assess for rickets osteopenia |
Dental | Dental exam to assess for enamel defects caries | Every 6 mos Ocular manifestations |
Source: GeneReviews — "Cystinosis"
Phenotype severity distribution: 4 always present features.
Estimated prevalence: Unknown (Unknown prevalence).
1 clinical trial registered, 1 recruiting. Interventions under study include other interventions. Research is primarily sponsored by academic and government institutions.
9 publications have been identified in PubMed for juvenile nephropathic cystinosis. Research spans Case Report / Case Series (44%), Epidemiology / Natural History (33%), and Diagnostic / Biomarker (11%).
de Vreugd A (2026). [PMID: 42229032](https://pubmed.ncbi.nlm.nih.gov/42229032/). *Mol Genet Metab*. [Epidemiology / Natural History]
Abou-Jaoude M (2025). [PMID: 40254074](https://pubmed.ncbi.nlm.nih.gov/40254074/). *Transplant immunology*. [Case Report / Case Series]
Elenberg E (2025). [PMID: 40143950](https://pubmed.ncbi.nlm.nih.gov/40143950/). *Kidney international reports*. [Epidemiology / Natural History]
Cislaru A (2025). [PMID: 40843950](https://pubmed.ncbi.nlm.nih.gov/40843950/). *Glycobiology*. [Diagnostic / Biomarker]
Medaer L (2024). [PMID: 38607085](https://pubmed.ncbi.nlm.nih.gov/38607085/). *Cells*. [Basic Science / Preclinical]
El Ghoul K (2024). [PMID: 38224843](https://pubmed.ncbi.nlm.nih.gov/38224843/). *Transplant immunology*. [Case Report / Case Series]
Üzüm S (2024). [PMID: 39205450](https://pubmed.ncbi.nlm.nih.gov/39205450/). *Turkish journal of ophthalmology*. [Case Report / Case Series]
Wu CW (2024). [PMID: 39113682](https://pubmed.ncbi.nlm.nih.gov/39113682/). *Frontiers in genetics*. [Epidemiology / Natural History]
Kawamura M (2024). [PMID: 39192178](https://pubmed.ncbi.nlm.nih.gov/39192178/). *BMC nephrology*. [Case Report / Case Series]
Data assembled from 8 of 12 sources · Last updated Sep 19, 2026, 9:40 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Findings in common w/cystinosis are renal Fanconi syndrome occurrence of eye findings. The absence of CKD in Wilson disease distinguishes it from cystinosis. CLCN5 OCRL |
— |
Dent disease | XL | Disorder of proximal renal tubular dysfunction characterized by LMW proteinuria, hypercalciuria, at least 1 additional finding (e.g., nephrocalcinosis, nephrolithiasis, hematuria, hypophosphatemia, CKD). | Finding in common w/cystinosis is renal tubular dysfunction. FAH | — |
Tyrosinemia type I | AR | Usually presents in young infants w/severe liver involvement or later in the 1st yr w/liver dysfunction renal tubular dysfunction assoc w/poor growth rickets. G6PC1 SLC37A4 | — | — |
Glycogen storage disease type I | AR | Characterized by accumulation of glycogen fat in liver kidneys resulting in hepatomegaly nephromegaly. Severely affected infants present in neonatal period w/severe hypoglycemia due to fasting intolerance. | — | — |
Classic galactosemia | AR | Can result in feeding problems, poor growth, hepatocellular damage, bleeding, E coli sepsis in untreated infants. Both tubular reabsorption glomerular filtration can be impaired. | — | — |
OCRL | Lowe syndrome (oculocerebrorenal syndrome) | XL | In males, Lowe syndrome involves eyes (cataracts, glaucoma, decreased visual acuity), CNS (hypotonia, ID), kidneys (Fanconi syndrome). Slowly progressive glomerulosclerosis kidney failure are often noted after age 10 yrs. | Similar renal findings in Lowe syndrome cystinosis. |
Source: GeneReviews — "Cystinosis"
AI-curated news mentioning juvenile nephropathic cystinosis
Updated Sep 4, 2026
A new study explores the pathogenesis and outcomes of metabolic bone disease associated with cystinosis. This research provides insights that could inform future therapeutic strategies for affected patients.
A recent study published in PubMed highlights the long-term outcomes of renal transplantation in patients with cystinosis. The findings provide valuable insights into the effectiveness of transplantation for this rare disease.
The NHS has approved the routine use of delayed-release mercaptamine for treating cystinosis. This decision enhances treatment options for patients suffering from this rare metabolic disorder.
The NHS has approved a delayed-release treatment for cystinosis, expanding options for eligible patients. This decision enhances the therapeutic landscape for managing this rare condition.
New clinical practice recommendations have been published for the diagnosis and management of nephropathic cystinosis. These guidelines aim to improve patient outcomes through standardized care practices.